Eton Pharmaceuticals reports record Q2 revenue, raises 2026 guidance
Eton Pharmaceuticals reports second-quarter revenue of $37.6 million, up 99% year over year, and raises 2026 revenue guidance to exceed $145 million while lifting its adjusted EBITDA margin outlook to above 35%.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.